Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  The Lancet Diabetes and Endocrinology

• Publication date

  2016-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S2213-8587(16)00039-5PMID 26969516
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.

  2016cited by this paper
• Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.

  2016cited by this paper
• Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes

  2015cited by this paper
• Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.

  2015cited by this paper
• Effects of sitagliptin on counter‐regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double‐blind placebo‐controlled crossover study

  2015cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2015cited by this paper
• Effect of Repeated Glucagon Doses on Hepatic Glycogen in Type 1 Diabetes: Implications for a Bihormonal Closed-Loop System

  2015cited by this paper
• Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes

  2015cited by this paper
• Restoration of the insulinotropic effect of glucose‐dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase‐4 inhibitors

  2015cited by this paper
• Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial (EASE‐1)

  2015cited by this paper
• Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.

  2015cited by this paper
• Sotagliflozin as a potential treatment for type 2 diabetes mellitus

  2015cited by this paper
• Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study

  2015cited by this paper
• Exploring the Potential of the SGLT 2 Inhibitor Dapagli fl ozin in Type 1 Diabetes : A Randomized , Double-Blind , Placebo-Controlled Pilot Study

  2014cited by this paper
• Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

  2014cited by this paper
• Outpatient glycemic control with a bionic pancreas in type 1 diabetes.

  2014cited by this paper
• Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

  2014cited by this paper
• Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.

  2014cited by this paper
• Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial

  2014cited by this paper
• Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus

  2014cited by this paper
• Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.

  2014cited by this paper
• Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)

  2014cited by this paper
• Type 1 Diabetes Treatment Beyond Insulin

  2013cited by this paper
• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.

  2013cited by this paper
• Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.

  2013cited by this paper
• Incretin hormones and the satiation signal

  2013cited by this paper
• Update on Cardiovascular Outcomes at 30 Years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study

  2013cited by this paper
• Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.

  2013cited by this paper
• Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.

  2012cited by this paper
• RECOMMANDATIONS 2012 EN DIABÉTOLOGIE: Prise en charge de l'hyperglycémie dans le diabète de type 2: une approche centrée sur le patient

  2012cited by this paper
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2012cited by this paper
• Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review

  2011cited by this paper
• Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function

  2011cited by this paper
• Biology of human sodium glucose transporters.

  2011cited by this paper
• Na+-d-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion

  2011cited by this paper
• Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double‐blind, randomized, crossover trial

  2011cited by this paper
• Liraglutide as additional treatment for type 1 diabetes.

  2011cited by this paper
• Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function

  2011cited by this paper
• The use of metformin in type 1 diabetes: a systematic review of efficacy

  2010cited by this paper
• Insulin Resistance, Defective Insulin-Mediated Fatty Acid Suppression, and Coronary Artery Calcification in Subjects With and Without Type 1 Diabetes

  2010cited by this paper
• Effects of Exenatide Alone and in Combination With Daclizumab on β-Cell Function in Long-Standing Type 1 Diabetes

  2009cited by this paper
• Temporal patterns in overweight and obesity in Type 1 diabetes

  2009cited by this paper
• Impaired Hyperglycemia-Induced Delay in Gastric Emptying in Patients With Type 1 Diabetes Deficient for Islet Amyloid Polypeptide

  2008cited by this paper
• The addition of rosiglitazone to insulin in adolescents with type 1 diabetes and poor glycaemic control: a randomized‐controlled trial

  2008cited by this paper
• Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study

  2008cited by this paper
• Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

  2008cited by this paper
• Effect of Vildagliptin on Glucagon Concentration During Meals in Patients with Type 1 Diabetes

  2008cited by this paper
• Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials

  2008cited by this paper
• Effect of pioglitazone therapy in lean type 1 diabetes mellitus.

  2007cited by this paper
• The physiology of glucagon-like peptide 1.

  2007cited by this paper
• Dipeptidyl Peptidase-4 Inhibitors

  2007cited by this paper
• Insulin Resistance, the Metabolic Syndrome, and Complication Risk in Type 1 Diabetes

  2007cited by this paper
• Biology of incretins: GLP-1 and GIP.

  2007cited by this paper
• A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes

  2007cited by this paper
• The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• Paradoxical Stimulation of Glucagon Secretion by High Glucose Concentrations

  2006cited by this paper
• Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes.

  2006cited by this paper
• AMP‐activated protein kinase: role in metabolism and therapeutic implications

  2006cited by this paper
• Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.

  2006cited by this paper
• Relationship of Fasting and Hourly Blood Glucose Levels to HbA1c Values

  2006cited by this paper
• Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

  2005cited by this paper
• The effect of rosiglitazone on overweight subjects with type 1 diabetes.

  2005cited by this paper
• Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study.

  2005cited by this paper
• Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes

  2005cited by this paper
• Glucagon‐like peptide 1(GLP‐1) in biology and pathology

  2005cited by this paper
• The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin‐induced hypoglycaemia in patients with type 1 diabetes

  2005cited by this paper
• Psychosocial problems and barriers to improved diabetes management: results of the Cross‐National Diabetes Attitudes, Wishes and Needs (DAWN) Study

  2005cited by this paper
• Glucagon-like peptide-1 prevents beta cell glucolipotoxicity

  2004cited by this paper
• Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trial

  2004cited by this paper
• Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.

  2003cited by this paper
• Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

  2003cited by this paper
• Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

  2003cited by this paper
• The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.

  2003cited by this paper
• Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

  2003cited by this paper
• Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.

  2002cited by this paper
• A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.

  2002cited by this paper
• Insulin resistance, intra-abdominal fat, cardiovascular risk factors, and androgens in healthy young women with type 1 diabetes mellitus.

  2002cited by this paper
• The Human Amylin Analog, Pramlintide, Reduces Postprandial Hyperglucagonemia in Patients with Type 2 Diabetes Mellitus

  2002cited by this paper
• Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition.

  2000cited by this paper
• The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.

  1999cited by this paper
• Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group.

  1999cited by this paper
• Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM

  1998cited by this paper
• Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Amylinʼs physiology and its role in diabetes

  1997cited by this paper
• Pharmacokinetics and Pharmacodynamics of AC137 (25,28,29 Tripro‐Amylin, Human) After Intravenous Bolus and Infusion Doses in Patients with Insulin‐Dependent Diabetes

  1996cited by this paper
• Combined Therapy with Insulin and Sulfonylurea for the Treatment of New-Onset Insulin-Dependent Diabetes Mellitus

  1996cited by this paper
• Glucagon-Like Peptide I Reduces Postprandial Glycemic Excursions in IDDM

  1995cited by this paper
• Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM

  1995cited by this paper
• Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

  1995cited by this paper
• Adverse Events and Their Association With Treatment Regimens in the Diabetes Control and Complications Trial

  1995cited by this paper
• The use of glipizide combined with intensive insulin treatment for the induction of remissions in new onset adult type I diabetes.

  1993cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Amylin concentrations and glucose control.

  1992cited by this paper
• Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.

  1992cited by this paper

• Glucagon in Pediatric Metabolic Disorders: Pathophysiology and Therapeutic Perspectives

  2025cites this paper
• Comparative efficacy and safety of oral hypoglycaemic drugs as adjunctive therapy in the management of type 1 diabetes mellitus: A systematic review and meta‐analysis

  2025influential citation
• "Comprehensive Investigation into the Discrete Toxicity of Curcumin on β-cell Viability and insulin secretion".

  2025cites this paper
• Abdominal Low-intensity Pulsed Ultrasound Therapy Mitigates Intestinal Damage and Microbial Dysbiosis in Diabetic Mice.

  2025cites this paper
• Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance

  2025cites this paper
• Research progress of cysteine transporter SLC7A11 in endocrine and metabolic diseases

  2025cites this paper
• Exploring the influencing factors of non-insulin drug prescriptions in discharged patients with type 1 diabetes

  2024cites this paper
• Effect of the sodium-glucose cotransporter-2 inhibitor, DWP16001, as an add-on therapy to insulin for diabetic dogs: A pilot study.

  2024cites this paper
• Pharmacotherapy for chronic obesity management: a look into the future

  2023cites this paper
• Concept for a Unidirectional Release Mucoadhesive Buccal Tablet for Oral Delivery of Antidiabetic Peptide Drugs Such as Insulin, Glucagon-like Peptide 1 (GLP-1), and their Analogs

  2023cites this paper
• N-acetyl-L-cysteine alleviates FUNDC1-mediated mitophagy by regulating mitochondrial dynamics in type 1 diabetic nephropathy canine.

  2023cites this paper
• Dioscin: Therapeutic potential for diabetes and complications.

  2023cites this paper
• Linagliptin in combination with insulin suppresses apoptotic unfolded protein response in ovaries exposed to type 1 diabetes

  2023cites this paper
• Targeting IL-12 family cytokines: A potential strategy for type 1 and type 2 diabetes mellitus.

  2023cites this paper
• The effect of sodium-glucose cotransporter 2 inhibitors as an adjunct to insulin in patients with type 1 diabetes assessed by continuous glucose monitoring: A systematic review and meta-analysis.

  2023cites this paper
• Treating obesity in type 1 diabetes mellitus – review of efficacy and safety

  2023cites this paper
• The Ameliorative Effects of Selenium Nanoparticles (SeNPs) on Diabetic Rat Model: A Narrative Review

  2023cites this paper
• Highlighting the Role of Obesity and Insulin Resistance in Type 1 Diabetes and Its Associated Cardiometabolic Complications

  2022cites this paper
• Long-acting amylin analogues for the management of obesity

  2022cites this paper
• Effects of Adjuvant Medications on A1C, Body Mass Index, and Insulin Requirements among Patients with Type 1 Diabetes

  2022cites this paper
• A Network Meta-Analysis of the Dose–Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes

  2022cites this paper
• A systematic review and dose-response meta-analysis on the efficacy of dapagliflozin in patients with type 1 diabetes mellitus.

  2021cites this paper
• Clinical characteristics and management of type 1 diabetes in Spain. The SED1 study.

  2021cites this paper
• Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump‐treated type 1 diabetes

  2021cites this paper
• In vitro antidiabetic, anti-inflammatory and antioxidant potential of the ethanol extract of Uromastyx hardwickii skin

  2021cites this paper
• Prolonged Honeymoon Period in a Thai Patient with Adult-Onset Type 1 Diabetes Mellitus

  2021cites this paper
• Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial

  2021cites this paper
• Automated Diagnosis of Diabetes Mellitus Based on Machine Learning

  2021cites this paper
• Using adjuvant pharmacotherapy in the treatment of type 1 diabetes

  2021influential citation
• Plant Alkaloids with Antidiabetic Potential

  2021cites this paper
• Wearable Glucose Monitoring and Implantable Drug Delivery Systems for Diabetes Management

  2021cites this paper
• Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era

  2021cites this paper
• Nanoparticulate tablet dosage form of lisofylline-linoleic acid conjugate for type 1 diabetes: in situ single-pass intestinal perfusion (SPIP) studies and pharmacokinetics in rat

  2021cites this paper
• Non-Insulin Antidiabetes Treatment in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

  2021cites this paper
• Clinical characteristics and management of type 1 diabetes in Spain. The SED1 study.

  2021cites this paper
• Effect of eugenol treatment in hyperglycemic murine models: A meta-analysis.

  2021cites this paper
• An Intelligent Diabetes Diagnostic Prediction System Using Ensemble Classifier

  2020cites this paper
• Efficacy and Safety of SGLT2 Inhibitors in Type 1 Diabetes After the Introduction of an Off-Label Use Protocol for Clinical Practice

  2020cites this paper
• Current status of metformin in addition to insulin therapy in adult patients with type 1 diabetes mellitus: An analysis from the Guangdong Type 1 Diabetes Mellitus Translational Medicine Study

  2020cites this paper
• GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?

  2020cites this paper
• NF-κB inhibits the occurrence of type 1 diabetes through microRNA-150-dependent PUMA degradation.

  2020cites this paper
• Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial.

  2020influential citation
• SGLT2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes.

  2020cites this paper
• Short- and medium-term efficacy of sodium glucose cotransporter 2 (SGLT-2) inhibitors for the treatment of type 1 diabetes: systematic review and meta-analysis.

  2020cites this paper
• Comparative efficacy and safety of glucose‐lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta‐analysis

  2020cites this paper
• Latest Therapies for Type 1 Diabetes: Exsisting Setup and “Post-Insulin” Standpoints

  2020cites this paper
• Adjunctive therapies in type 1 diabetes mellitus.

  2020cites this paper
• Il trattamento del diabete di tipo 1: dalle nuove insuline ai farmaci orali

  2019cites this paper
• Changing the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited

  2019cites this paper
• Urocortin 2 Gene Transfer Improves Glycemic Control and Reduces Retinopathy and Mortality in Murine Insulin Deficiency

  2019cites this paper
• Brain Signalling Systems: A target for treating Type I Diabetes Mellitus.

  2019cites this paper
• Isolation, characterization, and therapeutic activity of bergenin from marlberry (Ardisia colorata Roxb.) leaf on diabetic testicular complications in Wistar albino rats

  2019cites this paper
• Safety and efficacy of sodium glucose co‐transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: A meta‐analysis of randomized controlled trials

  2019cites this paper
• Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18–50 years

  2019cites this paper
• In Vitro Digestion of Microcapsule Carriers for Oral Delivery of Bioactive Compounds for Diabetes Treatment and Their Inhibitory Effect on the DPP-4 Enzyme

  2019cites this paper
• University of Dundee Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 1850 years

  2019cites this paper
• Avaliação molecular dos polimorfismos genéticos na susceptibilidade à nefropatia diabética por alterações hemodinâmicas e endoteliais

  2018cites this paper
• Empagliflozin as an adjunctive therapy for type 1 diabetes.

  2018cites this paper
• A soft computing approach for diabetes disease classification

  2018cites this paper
• Oral formulation of DPP-4 inhibitor plus Quercetin improves metabolic homeostasis in type 1 diabetic rats

  2018cites this paper
• Ikenouye Title : Characterization of the ATCC α-TC 1-6 Pancreatic Alpha Cell Line to Study Glucagon Secretion Advisor

  2018cites this paper
• Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes

  2018cites this paper
• Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial

  2018cites this paper
• Possible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes

  2018cites this paper
• Minireview of Adverse Effects of Some Drugs Used in Diabetes Mellitus

  2018cites this paper
• Altered T‐cell subsets and transcription factors in latent autoimmune diabetes in adults taking sitagliptin, a dipeptidyl peptidase‐4 inhibitor: A 1‐year open‐label randomized controlled trial

  2018cites this paper
• Glycemic Management in Adults With Type 1 Diabetes.

  2018cites this paper
• The Artificial Pancreas and Meal Control: An Overview of Postprandial Glucose Regulation in Type 1 Diabetes

  2018cites this paper
• Glucagon treatment in type 1 diabetes -with focus on restoring plasma glucose during mild hypoglycemia
.

  2018cites this paper
• Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4‐week, double‐blind, randomized, placebo‐controlled phase 2 trial

  2018cites this paper
• Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis.

  2018cites this paper
• Adjunctive therapy for glucose control in patients with type 1 diabetes

  2018influential citation
• Recent research trend in cell and drug delivery system for type 1 diabetes treatment

  2018cites this paper
• Role of Noninsulin Therapies in the Treatment of Type 1 Diabetes

  2018influential citation
• Treatment with GLP-1 Receptor Agonists

  2018cites this paper
• Acute renal metabolic effect of metformin assessed with hyperpolarised MRI in rats

  2018cites this paper
• Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes

  2017cites this paper
• Pharmacotherapy options for pediatric diabetes

  2017cites this paper
• Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.

  2017cites this paper
• Characterization of the ATCC α-TC1-6 Pancreatic Alpha Cell Line to Study Glucagon Secretion

  2017cites this paper
• Modeling Pharmacokinetics and Pharmacodynamics of Glucagon for Simulation of the Glucoregulatory System in Patients with Type 1 Diabetes.

  2017cites this paper
• A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.

  2017cites this paper
• [Prevalence of Dental Caries in Patients with Type 1 Diabetes Mellitus Treated with Multiple Insulin Injections and that of Individuals without Diabetes].

  2017cites this paper
• Effect of Oral Pre-Meal Administration of Betaglucans on Glycaemic Control and Variability in Subjects with Type 1 Diabetes

  2017cites this paper
• Pharmacological Treatment in Diabetes Mellitus Type 1 – Insulin and What Else?

  2017cites this paper
• Use of Adjuvant Pharmacotherapy in Type 1 Diabetes: International Comparison of 49,996 Individuals in the Prospective Diabetes Follow-up and T1D Exchange Registries

  2017cites this paper
• Efficacy and safety of incretin-based drugs in patients with type 1 diabetes mellitus: A systematic review and meta-analysis.

  2017cites this paper
• The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis.

  2016cites this paper
• Blocking 5-HT2 receptor restores cardiovascular disorders in type 1 experimental diabetes

  2016cites this paper
• Adjunctive Role of Glucagon‐Like Peptide‐1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus

  2016cites this paper
• Hypertension in type 2 diabetes: impact of glucose-lowering medications

  2016cites this paper
• World Journal of Diabetes

  year unknowncites this paper
• Endocrinología, Diabetes y Nutrición

  year unknowncites this paper